- Home
- IVDA vs ONCO Comparison
IVDA vs ONCO Comparison
Compare IVDA & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVDA | ONCO |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 2.8M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IVDA | ONCO |
|---|---|---|
| Price | $0.42 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.4M | 192.6K |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.38 | 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,468,279.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.98 | N/A |
| 52 Week Low | $0.21 | $0.09 |
| 52 Week High | $2.24 | $6.73 |
Technical Indicators
Market Signals| Indicator | IVDA | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 61.93 | 45.96 |
| Support Level | $0.24 | $0.62 |
| Resistance Level | $0.42 | $0.86 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 52.18 | 47.82 |
Price Performance
Historical ComparisonAbout IVDA Iveda Solutions Inc.
Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.